Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial

NCT04613102 is registered in ClinicalTrials.gov with Elena Pope as lead sponsor.

NCT NCT04613102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04613102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of 3% Cannabidiol (CBD) Cream in Patients With Epidermolysis Bullosa: A Phase II/III Trial
Lead sponsor
Elena Pope
Phase
Phase 2/3
Overall status
Withdrawn
Start date
August 1, 2020
Completion date
December 30, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epidermolysis bullosa, itch, pain